Please assess the completion status of the following clinical trial:

Trial Title: A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is an ambulatory, community-dwelling male or nonpregnant female and is at least 18 years old at the Screening Visit. Lactating females must agree not to breastfeed.~* Patient has a diagnosis of GERD and reports experiencing GERD symptoms (heartburn or regurgitation) on ≥ 4 days per week during the 8 weeks before the Screening Visit while taking standard QD PPI therapy.~Exclusion Criteria:~* Patient may not meet any of the excluded conditions specified in the protocol~* Patient has any alarm symptoms including but not limited to GI bleeding, anemia, vomiting, dysphagia, or unexpected weight loss any time during the Screening or Pretreatment Periods~* Patient has a history of clinically significant hypersensitivity or allergies to any of the excipients contained in the study medication (active or placebo).~NOTE: Additional inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Matching placebo twice daily
- 500 mg IW-3718 (Type: EXPERIMENTAL): 500 mg IW-3718 twice daily
- 1000 mg IW-3718 (Type: EXPERIMENTAL): 1000 mg IW-3718 twice daily
- 1500 mg IW-3718 (Type: EXPERIMENTAL): 1500 mg IW-3718 twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).